definiens: shall mean, with respect to any Licensed Human Therapeutic Product, the aggregate cash consideration received by OXIS or its Affiliates in consideration for the sublicense under the Licensed Patent Rights or Licensed Know - H ow Rights by OXIS or its Affiliates to a Third Part y sub - licensee with respect to such Licensed Human Therap eutic Product including royalties received by OXIS or its Affiliates based on sales of such Licensed Human Th erapeutic Product by such sub - licensee, but excludi ng amounts received to reimburse OXIS ’ or its Affiliat es ’ cost to perform research, development or simila r services conducted for such Licensed Human Therapeutic Produ ct after signing the agreement with the Third Party, in reimbursement of patent or other out - of - pocket expe nses relating to such Licensed Human Therapeutic Pr oduct, or in consideration for the purchase of any debt or securities of OXIS or its Affiliates